Company intelligence / Profile preview
Zelos Therapeutics
Conshohocken, Pennsylvania, USAir.neximmune.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Phase 3
01
Overview
ZT‑031 (Ostabolin-C), a proprietary cyclic parathyroid hormone analog, demonstrated strong bone formation activity with rapid onset and clinically significant increases in bone mineral density at low toxicity doses. The subcutaneous formulation completed a successful 12-month Phase 2 trial in postmenopausal women with low bone mass. Intranasal and inhaled versions were also developed through partnerships.[6] The company planned to enter Phase 3 trials before restructuring as Azelon Pharmaceuticals.[7] As Azelon, the nasal spray ZT‑034 entered early clinical studies.
- Therapeutic areas
- OtherEndocrinologyNephrology
- Modalities
- Peptides (parathyroid hormone analogs)Small proteins[6][8][10]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Aegis Therapeutics LLC – collaboration on intranasal delivery using Intravail® technology[5]Nektar Therapeutics – collaboration on inhaled powder formulation of Ostabolin-C using Nektar’s inhaler device technology[8][10]
Beyond the preview
Go deeper on Zelos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zelos Therapeutics.